S
Steven R. Cummings
Researcher at University of California, San Francisco
Publications - 628
Citations - 111006
Steven R. Cummings is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Osteoporosis & Hip fracture. The author has an hindex of 158, co-authored 579 publications receiving 104007 citations. Previous affiliations of Steven R. Cummings include Veterans Health Administration & California Pacific Medical Center.
Papers
More filters
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.
Steven R. Cummings,Michael C. Nevitt,Warren S. Browner,Katie L. Stone,Kathleen M. Fox,Kristine E. Ensrud,Jane A. Cauley,Dennis Black,Thomas M. Vogt +8 more
TL;DR: Women with multiple risk factors and low bone density have an especially high risk of hip fracture and maintaining body weight, walking for exercise, avoiding long-acting benzodiazepines, minimizing caffeine intake, and treating impaired visual function are among the steps that may decrease the risk.
Journal ArticleDOI
Epidemiology and outcomes of osteoporotic fractures.
TL;DR: In this paper, epidemiological research was done and used to identify individuals at high risk of disabling fractures, thereby allowing careful allocation of expensive treatments to individuals most in need, which could potentially be as expensive as medical treatment of fractures.
Journal ArticleDOI
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger,Dennis M. Black,Bruce H. Mitlak,Ronald Keith Knickerbocker,Thomas Nickelsen,Harry K. Genant,Claus Christiansen,Pierre D. Delmas,Jose R. Zanchetta,J. A. Stakkestad,Claus C. Glüer,Kathryn A. Krueger,Fredric J. Cohen,Stephen Eckert,Kristine E. Ensrud,Louis V. Avioli,Paul Lips,Steven R. Cummings +17 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) study as mentioned in this paper evaluated the effect of raloxion hydrochloride therapy on risk of vertebral and non-vertebral fractures.
Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings,Javier San Martin,Michael R. McClung,Ethel S. Siris,Richard Eastell,Ian R. Reid,Pierre D. Delmas,Holly B. Zoog,M. Austin,Andrea Wang,Stepan Kutilek,Silvano Adami,Jose R. Zanchetta,Cesar Libanati,Suresh Siddhanti,Claus Christiansen +15 more
TL;DR: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.